R. Maziarz

发表

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma

G. Salles, H. Holte, Serafino Pantano, 2019, The New England journal of medicine.

A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy.

T. Fleming, E. Anaissie, R. Beveridge, 2004, Leukemia research.

Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

A. Nademanee, J. Dipersio, G. Bridger, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

A. Nademanee, J. Dipersio, J. Kaufman, 2009, Blood.

Translin/TRAX Deficiency Affects Mesenchymal Differentiation Programs and Induces Bone Marrow Failure

S. Asano, J. Matsuda, R. Maziarz, 2012 .

Peripheral-blood stem cells versus bone marrow from unrelated donors.

P. Westervelt, S. Mineishi, D. Porter, 2012, The New England journal of medicine.

Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.

T. Eberlein, I. Yoshino, G. Peoples, 1994, Journal of immunology.

Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?

M. Mauro, R. Maziarz, 2006, Mayo Clinic proceedings.

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

H. Deeg, P. Hari, M. Sorror, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mechanical ventilation in hematopoietic stem cell transplant patients: is there need for reevaluation?

D. J. Nichols, M. Haupt, R. Maziarz, 1999, Chest.

Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL.

M. Kersten, G. Salles, Iulian Pruteanu-Malinici, 2020, Blood advances.

the significance of telomere length measurements TERC and TERT gene mutations in patients with bone marrow failure and

J. Ivanovich, A. Shimamura, J. Lipton, 2013 .

TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements.

J. Ivanovich, P. An, A. Shimamura, 2009, Blood.

No increased mortality from donor or recipient hepatitis B‐ and/or hepatitis C‐positive serostatus after related‐donor allogeneic hematopoietic cell transplantation

M. Aljurf, M. Horowitz, J. Wingard, 2012, Transplant infectious disease : an official journal of the Transplantation Society.

Single and multiple dose MultiStem (multipotent adult progenitor cell) therapy prophylaxis of acute graft-versus-host disease in myeloablative allogeneic hematopoietic cell transplantation: a phase 1 trial.

H. Lazarus, S. Devine, R. Maziarz, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impending challenges in the hematopoietic stem cell transplantation physician workforce.

H. Heslop, M. Horowitz, C. Anasetti, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?

R. Maziarz, 2008, Current opinion in hematology.

In Vitro Engagement of CD3 and CD28 Corrects T Cell Defects in Chronic Lymphocytic Leukemia1

E. Robinet, P. Tiberghien, C. Ferrand, 2005, The Journal of Immunology.

Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.

J. Sierra, J. Dipersio, B. George, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria

S. Jhanwar, H. Thaler, K. Nafa, 2001, British journal of haematology.

Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission.

B. Druker, M. Mauro, R. Maziarz, 2004, Leukemia research.

Chronic Graft-Versus-Host Disease, Non-Relapse Mortality and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A CIBMTR Analysis.

J. Pidala, L. Lekakis, V. Bhatt, 2021, Transplantation and cellular therapy.

Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged ≥70 years.

U. Borate, E. Traer, R. Maziarz, 2019, Hematology/oncology and stem cell therapy.

Explaining Family Caregiver Role Strain Following Autologous Blood and Marrow Transplantation

L. Nail, D. Eldredge, R. Maziarz, 2006, Journal of psychosocial oncology.

Hematopoietic stem cell transplantation for myelofibrosis: where are we now?

Angela G. Fleischman, R. Maziarz, A. Fleischman, 2013, Current opinion in hematology.

Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

Alan M. Miller, R. Vij, W. Wood, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Role of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia Patients in the Era of Tyrosine Kinase Inhibitors

R. Maziarz, 2010 .

Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever

R. Maziarz, J. Bubalo, G. Cherala, 2008, Antimicrobial Agents and Chemotherapy.

Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial.

D. Maloney, Junlong Li, S. Schuster, 2020, Blood advances.

Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

M. Kersten, G. Salles, U. Jaeger, 2017 .

Optimal benefits for hematopoietic stem cell transplantation: a consensus opinion.

K. Komanduri, R. Maziarz, Stephanie H Farnia, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic

P. Riedell, S. Grupp, M. Perales, 2020, Biology of Blood and Marrow Transplantation.

transplantation for follicular lymphoma Comparison of autologous and allogeneic hematopoietic stem cell

J. Armitage, J. Vose, M. Horowitz, 2013 .

Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.

M. Norkin, W. Wood, M. Sorror, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

J. Vose, Sonali M. Smith, P. Hari, 2012, Blood.

In Vitro Engagement of CD 3 and CD 28 Corrects T Cell Defects in Chronic Lymphocytic Leukemia 1

E. Robinet, P. Tiberghien, C. Ferrand, 2005 .

Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia

A. Goy, M. Verneris, R. Maziarz, 2021, Journal for ImmunoTherapy of Cancer.

Autologous and Allogeneic Hematopoietic Cell Transplantation for Diffuse Large B-cell Lymphoma-Type Richter Syndrome.

C. Jacobson, Q. Bashir, Z. DeFilipp, 2021, Blood advances.

Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.

A. Nademanee, J. Dipersio, J. Kaufman, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma

R. Maziarz, B. Hayes-Lattin, T. Bains, 2014, Leukemia & lymphoma.

lymphoma: myeloablative or reduced intensity? Conditioning regimens for allotransplants for diffuse large B-cell

Sonali M. Smith, P. Hari, P. Armand, 2012 .

Novel H1N1 influenza in hematopoietic stem cell transplantation recipients: two centers' experiences.

G. Forrest, R. Maziarz, E. Ball, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease.

A. Weinberg, R. Maziarz, T. Tittle, 1997, Blood.

Selective depletion of myelin–reactive T cells with the anti–OX–40 antibody ameliorates autoimmune encephalomyelitis

D. Bourdette, E. Engleman, A. Weinberg, 1996, Nature Medicine.

Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia

M. Horowitz, J. Goldman, Stephanie J. Lee, 2007, British journal of haematology.

Central Nervous System Failure in Patients with Chronic Myelogenous Leukemia Lymphoid Blast Crisis and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with Imatinib (STI-571)

J. Ford, B. Druker, P. Curtin, 2004, Leukemia & lymphoma.

Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer.

R. Vij, K. Trinkaus, P. Fracasso, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

total body irradiation for relapsed and refractory mantle cell lymphoma Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy

R. Storb, B. Sandmaier, B. Storer, 2013 .

Lifetime Costs for Treated Follicular Lymphoma Patients in the US

T. Delea, R. Maziarz, Q. Ma, 2021, PharmacoEconomics.

Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research.

S. Montoto, P. Hari, D. Maloney, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic stem-cell transplantation in renal-cell carcinoma

T. Beer, R. Maziarz, B. Hayes-Lattin, 2001, Current oncology reports.

A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.

J. Vose, J. Winter, P. Hari, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia.

W. Wood, M. Horowitz, Stephanie J. Lee, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR).

M. Sorror, J. Wingard, M. Gilleece, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma

R. Maziarz, Y. Hao, L. Eldjerou, 2018, Leukemia & lymphoma.

Aprepitant Pharmacokinetics and Assessing the Impact of Aprepitant on Cyclophosphamide Metabolism in Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation

R. Maziarz, J. McCune, J. Bubalo, 2012, Journal of clinical pharmacology.

Mesenchymal stromal cells: potential roles in graft‐versus‐host disease prophylaxis and treatment

R. Maziarz, 2016, Transfusion.

Is comparative effectiveness research effective ? Abandonment of high dose chemotherapy / hematopoietic cell transplants for breast cancer March 9 , 2010

R. Maziarz, C. Lemaistre, D. Howard, 2010 .

Engrafted donor-derived clonal hematopoiesis after allogenic hematopoietic cell transplantation is associated with chronic GVHD requiring immunosuppressive therapy, but no adverse impact on OS or relapse.

Philipp W. Raess, E. Traer, P. Raess, 2021, Transplantation and cellular therapy.

Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome

H. Deeg, D. Porter, G. Gui, 2020, medRxiv.

BMT CTN State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.

E. Leifer, P. Hari, H. Heslop, 2021, Transplantation and cellular therapy.

Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison

M. Kersten, J Zhang, S. Schuster, 2022, Leukemia & lymphoma.

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.

M. Kersten, G. Salles, H. Holte, 2021, The Lancet. Oncology.

Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial.

D. Maloney, Junlong Li, S. Schuster, 2020, Blood advances.

Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion.

H. Holte, U. Jäger, M. Bishop, 2019, Blood advances.

Distinct effects of interferon-gamma and MHC class I surface antigen levels on resistance of the K562 tumor cell line to natural killer-mediated lysis.

D. Faller, R. Maziarz, S. Burakoff, 1990, Cellular immunology.

Autologous haematopoietic cell transplantation for non‐Hodgkin lymphoma with secondary CNS involvement

J. Vose, S. Montoto, P. Hari, 2013, British journal of haematology.

Specific Immunotherapy for Non-Hodgkin's

R. Maziarz, 2016 .

Specific Immunotherapy for Non-Hodgkin’s Lymphoma

R. Maziarz, J. Leis, 2001 .

Abandonment of high-dose chemotherapy/hematopoietic cell transplants for breast cancer following negative trial results.

P. McCarthy, H. Lazarus, D. Howard, 2011, Health services research.

β2-Microglobulin from serum associates with several class I antigens expressed on the surface of mouse L-cells

C. Murre, R. Maziarz, C. Terhorst, 1985 .

Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.

A. Krishnan, P. Hari, R. Kyle, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The human HLA specific monoclonal antibody W6/32 recognizes a discontinuous epitope within the α2 domain of murine H-2Db

J. Strominger, R. Maziarz, J. Fraser, 1986, Immunogenetics.

Coexpression of the human HLA-A2 or HLA-B7 heavy chain gene and human beta 2-microglobulin gene in L cells.

H. Spits, R. Maziarz, C. Terhorst, 1984, Journal of immunology.

Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial.

P. Westervelt, M. Horowitz, Stephanie J. Lee, 2016, JAMA oncology.

Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.

B. Storer, K. van Besien, Stephanie J. Lee, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Viral-restricted cytolytic T lymphocyte recognition of hybrid human-murine class I histocompatibility antigens.

R. Maziarz, S. Burakoff, C. Reiss, 1986, Cellular immunology.

Philadelphia chromosome-positive acute lymphoblastic leukemia: Impact of imatinib treatment on remission induction and allogeneic stem cell transplantation

T. Kovacsovics, R. Maziarz, 2006, Current oncology reports.

Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.

J. Dipersio, R. Soiffer, R. Negrin, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Safety and efficacy of upfront plerixafor + G‐CSF versus placebo + G‐CSF for mobilization of CD34+ hematopoietic progenitor cells in patients ≥60 and <60 years of age with non‐Hodgkin's lymphoma or multiple myeloma

A. Nademanee, J. Dipersio, P. Stiff, 2013, American journal of hematology.

Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.

A. Nademanee, J. Dipersio, G. Bridger, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.

P. Hari, R. Kyle, Shaji K. Kumar, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Non—MHC—restricted target—cell lysis by a CD4−CD− TCRαβ T—cell line, as well as by TCR4gMδ T—cell lines, results from lymphokine—activated killing

J. Strominger, R. Maziarz, S. Burakoff, 2007 .

beta 2-Microglobulin from serum associates with several class I antigens expressed on the surface of mouse L-cells.

R. Maziarz, C. Terhorst, C. Bernabéu, 1985, Molecular immunology.

Double-negative (CD4-CD8-) lymphocytes bearing T-cell receptor alpha and beta chains in normal human skin.

J. Strominger, R. Maziarz, F. Hochstenbach, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Recognition of interspecies hybrid class I histocompatibility antigens by antigen-specific cytolytic T lymphocytes.

P. A. Biro, J. Strominger, R. Flavell, 1985, Proceedings of the National Academy of Sciences of the United States of America.

Novel subsets of human T cells (CD4+ CD8+ TCRγδ and CD4− CD8− TCRαβ) and T‐cell development

J. Strominger, R. Maziarz, S. Burakoff, 1989 .

Perspective: An International Fludarabine shortage: Supply Chain Issues Impacting Transplant and Immune Effector Cell Therapy Delivery.

D. Miklos, R. Maziarz, Amber H Diaz, 2022, Transplantation and cellular therapy.

Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?

M. Perales, F. Appelbaum, J. Liesveld, 2013, Blood.

Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma.

S. Montoto, Sonali M. Smith, P. Hari, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease.

P. Streeter, R. Maziarz, A. Raber, 2009, Cellular immunology.

Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation.

R. Beveridge, E. Rubenstein, R. Maziarz, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Imatinib mesylate: a novel immune suppressive agent?

R. Maziarz, 2004 .

The regulation of exogenous and endogenous class I MHC genes in a human tumor cell line, K562.

D. Faller, R. Maziarz, S. Burakoff, 1990, Molecular immunology.

Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.

E. Leifer, N. Geller, D. Porter, 2021, Transplantation and cellular therapy.

Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.

Alan M. Miller, M. Norkin, P. Hari, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplantation after ﬂudarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

M. Maris, R. Storb, B. Sandmaier, 2004 .

Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR® study

E. Guinan, M. Boeckh, M. Aljurf, 2016, Bone Marrow Transplantation.

Outcome of transplantation for myelofibrosis.

N. Kröger, M. Horowitz, R. Gale, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Graft‐versus‐host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutations

A. Olyaei, S. Orloff, R. Maziarz, 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Transplantation for chronic myelogenous leukemia: yes, no, maybe so…an Oregon perspective

M. Mauro, R. Maziarz, 2003, Bone Marrow Transplantation.

Proceedings From the Fourth Haploidentical Stem Cell Transplantation Symposium (HAPLO2016), San Diego, California, December 1, 2016.

P. Hari, Richard J. Jones, Jeffrey S. Miller, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pre-clinical safety testing supporting clinical use of allogeneic multipotent adult progenitor cells.

P. Streeter, R. Maziarz, A. Raber, 2008, Cytotherapy.

Prophylaxis of Acute GVHD Using Multistem® Stromal Cell Therapy: Preliminary Results After Administration of Single or Multiple Doses in a Phase 1 Trial

H. Lazarus, R. Maziarz, Robert Perry, 2012 .

Prophylaxis of Acute Gvhd Using Stromal Cell Therapy: Preliminary Results After Administration of Single or Multiple Doses of Multistem® in a Phase I Trial

H. Lazarus, R. Maziarz, Robert Perry, 2011 .

Stromal Stem Cell Therapy for Prophylaxis of Acute GVHD: Preliminary Results From a Phase 1 Trial

H. Lazarus, S. Devine, R. Maziarz, 2011 .

Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants.

J. Kurtzberg, J. Wingard, J. Bolaños-Meade, 2013, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.

J. Vose, M. Aljurf, R. Gale, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-cell Lymphomas.

P. Riedell, M. Perales, D. Porter, 2022, Transplantation and cellular therapy.

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.

J. Fay, B. Storer, J. Wingard, 2009, Blood.

The alpha-3 domain of class I MHC proteins influences cytotoxic T lymphocyte recognition of antigenic determinants located within the alpha-1 and alpha-2 domains.

J. Bluestone, R. Maziarz, S. Burakoff, 1988, Journal of immunology.

syndrome and acute myeloid leukemia Allogeneic transplantation for therapy-related myelodysplastic

J. Sierra, J. Dipersio, S. Tarima, 2011 .

Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.

J. Sierra, J. Dipersio, S. Tarima, 2010, Blood.

Clinical use of plerixafor in combination with granulocyte-colony stimulating factor in hematopoietic stem cell transplantation

R. Maziarz, Cedar Fowler, 2010 .

Human multipotent adult progenitor cells transcriptionally regulate fucosyltransferase VII.

R. Maziarz, N. Lehman, A. Raber, 2014, Cytotherapy.

Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.

M. Maris, R. Storb, B. Sandmaier, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Drug resistance in B‐cell chronic lymphocytic leukemia: Predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay

R. Braziel, R. Maziarz, K. Gatter, 2007, Cytometry. Part B, Clinical cytometry.

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.

E. Leifer, N. Geller, H. Deeg, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).

M. Maris, R. Storb, B. Sandmaier, 2007 .

Acute Lymphoblastic Leukemia

R. Maziarz, G. Hildebrandt, 2021, Blood and Marrow Transplant Handbook.

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

K. Owzar, C. Hofmeister, R. Vij, 2010 .

J. Szer, B. George, R. Gale, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.

M. Maris, R. Storb, B. Sandmaier, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update in the Epidemiology, Prophylaxis, and Treatment of Fungal Infections in Patients with Hematologic Disorders

R. Maziarz, B. Hayes-Lattin, 2004, Leukemia & lymphoma.

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.

A. Zander, J. Szer, M. Horowitz, 2008, Blood.

Design and Methods

S. Iacobelli, R. Brand, A. Nagler, 2022 .

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children (<18y) and Young adults (18–29y) with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis

W. Wood, R. Sparapani, R. Gale, 2016 .

Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience

P. Hari, M. Sorror, M. Maris, 2019, Bone Marrow Transplantation.

Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS.

Y. Liu, M. Aljurf, J. Szer, 2020, Blood advances.

Acute Lymphoblastic Leukemia : Impact of Imatinib Treatment on Remission Induction and Allogeneic Stem Cell Transplantation

T. Kovacsovics, R. Maziarz, Tibor Kovacsovics, 2006 .

Ph+ ALL: another success for imatinib

R. Maziarz, 2005 .

PROGNOSTIC FACTORS FOR OUTCOMES IN ALLOGENEIC TRANSPLANTATION FOR ADVANCED PHASES OF CHRONIC MYELOID LEUKEMIA IN THE IMATINIB ERA: A CIBMTR ANALYSIS

J. Cortes, J. Szer, M. Horowitz, 2011, Bone Marrow Transplantation.

Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.

S. Montoto, Sonali M. Smith, P. Hari, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma

M. Loriaux, G. Thomas, R. Amaravadi, 2017, Haematologica.

Phase II trial of parathyroid hormone after double umbilical cord blood transplantation.

E. Shpall, J. Wingard, K. Ballen, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase II Trial of Parathyroid Hormone following Double Umbilical Cord Blood Transplantation

E. Shpall, J. Wingard, K. Ballen, 2012 .

Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.

J. Dipersio, G. Bridger, G. Calandra, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström macroglobulinemia: evidence for a graft-versus-lymphoma effect

R. Storb, B. Sandmaier, D. Maloney, 2018, Haematologica.

Autopsy among recipients of stem cell transplant for hematologic malignancies in the modern era

E. Medvedova, R. Maziarz, L. Strasfeld, 2020, Bone Marrow Transplantation.

Biological activity of interleukin-2 bound to Candida albicans

R. Maziarz, S. Levitz, C. Treseler, 1992, Infection and immunity.

Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access

P. Kefalas, R. Maziarz, Stephanie Farnia, 2017, Stem cells translational medicine.

In Vitro Engagement of CD 3 and CD 28 Corrects T Cell Defects in Chronic Lymphocytic Leukemia 1

E. Robinet, P. Tiberghien, C. Ferrand, 2005 .

Managing particulates in cellular therapy.

M. Mccaman, R. Maziarz, J. Rowley, 2012, Cytotherapy.

Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.

E. Estey, M. Bar, B. Wood, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.

A. Nademanee, J. Dipersio, G. Calandra, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Tissue-Specific Progenitor and Stem Cells Solution-Phase Crosstalk and Regulatory Interactions Between Multipotent Adult Progenitor Cells and Peripheral Blood Mononuclear Cells

P. Wilmarth, R. Maziarz, A. Reddy, 2015 .

Killing of Cryptococcus neoformans by human peripheral blood mononuclear cells stimulated in culture.

R. Maziarz, S. Levitz, T. Farrell, 1991, The Journal of infectious diseases.

A gamma delta+ T-cell leukemia bearing a novel t(8;14)(q24;q11) translocation demonstrates spontaneous in vitro natural killer-like activity.

R. Arceci, J. Strominger, M. Kasai, 1992, Blood.

Modified HyperCVAD Versus Bortezomib‐HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma

E. Medvedova, R. Maziarz, E. Scott, 2018, Clinical lymphoma, myeloma & leukemia.

Outcomes of HLA Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative vs. Reduced-Intensity Conditioning Regimens

J. Cortes, M. Aljurf, I. Lewis, 2014 .

Chronic Graft-Versus-Host Disease

R. Maziarz, F. Abar, 2010 .

Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.

A. Nademanee, J. Dipersio, G. Bridger, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning.

M. Norkin, S. Mineishi, M. Krem, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Healthcare expenditures of older patients with AML are similar between HMA and intensive induction chemotherapy

R. Maziarz, R. Cook, Matthew Kearney, 2019, Leukemia & lymphoma.

Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901

E. Leifer, N. Geller, H. Deeg, 2015 .

Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States

R. Maziarz, V. Bollu, Hongbo Yang, 2022, Leukemia & lymphoma.

Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma

G. Salles, J Zhang, C. Tam, 2022, Blood advances.

Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age.

Stephanie J. Lee, P. McCarthy, H. Lazarus, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Treosulfan, Fludarabine and 2 Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with MDS and AML

E. Estey, M. Bar, B. Wood, 2014 .

Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.

M. Sorror, M. Maris, R. Storb, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular involvement of the pvt-1 locus in a gamma/delta T-cell leukemia bearing a variant t(8;14)(q24;q11) translocation

E. Macintyre, J. Strominger, R. Maziarz, 1992, Molecular and cellular biology.

Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors.

Stephanie J. Lee, P. McCarthy, H. Lazarus, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignancies.

M. Aljurf, B. George, M. Flowers, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.

R. Gale, P. Tiberghien, O. Ringdén, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MSCs in hematopoietic cell transplantation.

E. Horwitz, R. Maziarz, P. Kebriaei, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents.

W. Wood, M. Sorror, H. Lazarus, 2014, Biology of Blood and Marrow Transplantation.

Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant.

R. Maziarz, E. Wu, Lei Chen, 2016, International journal of hematologic oncology.

Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel

M. Kersten, G. Salles, U. Jaeger, 2018, Blood.

Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies

Philipp W. Raess, P. Raess, E. Nemecek, 2021, American journal of hematology.

M. Maris, R. Storb, B. Sandmaier, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Omidubicel Versus Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase III Randomized Study.

O. Frankfurt, G. Schiller, P. Stiff, 2021, Blood.

Overview of Hematopoietic Cell Transplantation and Cellular Therapy

R. Maziarz, 2021 .

Payment and Care for Hematopoietic Cell Transplantation Patients: Toward a Specialized Medical Home for Complex Care Patients.

M. Mcclellan, P. Hari, K. Komanduri, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Response to Letter from Demetrios S. Theodoropoulos, MD, DSc.

M. Horowitz, R. Maziarz, J. Gajewski, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Overview of Hematopoietic Stem Cell Transplantation

R. Maziarz, 2010 .

Life-Threatening Adenovirus Infections in the Setting of the Immunocompromised Allogeneic Stem Cell Transplant Patients

R. Maziarz, J. Dunlap, P. Stenzel, 2010, Advances in hematology.

Control of an Outbreak of Human Parainfluenza Virus 3 in Hematopoietic Stem Cell Transplant Recipients

R. Maziarz, D. Erdman, T. Peret, 2009, Biology of Blood and Marrow Transplantation.

Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning.

M. Sorror, M. Maris, R. Storb, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials.

M. Perales, F. Appelbaum, D. Porter, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

EFFECTS OF SPLEEN STATUS ON EARLY OUTCOMES AFTER HEMATOPOIETIC CELL TRANSPLANTATION

M. Pasquini, K. Ballen, U. Popat, 2012, Bone Marrow Transplantation.

Allogeneic stem cell transplantation for chronic myeloproliferative disorders and myelodysplastic syndromes: the question is "when?".

R. Mesa, A. Tefferi, R. Maziarz, 2003, Mayo Clinic proceedings.

Serial Transthoracic Ultrasonography Studies in Hematopoietic Cell Transplant Patients: A Tool for Early Lung Pathology Detection.

K. Gregory, R. Maziarz, Meihua Zhu, 2022, Ultrasound in medicine & biology.

Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis.

S. Primack, B. Druker, P. Curtin, 2004, Haematologica.

Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial

M. Kersten, G. Salles, U. Jaeger, 2019, Blood.

Autologous Stem Cell Transplant in the Era of Bortezomib-Based Induction for AL Amyloidosis – A Single Institution 11 Year Experience

C. Karam, E. Medvedova, R. Maziarz, 2018 .

Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.

T. Kovacsovics, R. Maziarz, S. Heitner, 2014, Clinical lymphoma, myeloma & leukemia.

Pure red cell aplasia associated with parvovirus B19 infection occurring late after allogeneic bone marrow transplantation

M. Heinrich, R. Maziarz, K. Gatter, 2004, American journal of hematology.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis.

W. Wood, R. Sparapani, R. Gale, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.

M. Horowitz, P. Armand, R. Soiffer, 2014, Blood.

Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial.

P. Hari, R. Storb, B. Sandmaier, 2013, Biology of Blood and Marrow Transplantation.

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.

H. Deeg, D. Porter, G. Gui, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Next‐generation sequencing‐defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse

R. Maziarz, R. Press, J. Lim, 2019, American journal of hematology.

Lenalidomide after stem-cell transplantation for multiple myeloma.

K. Owzar, C. Hofmeister, R. Vij, 2012, The New England journal of medicine.

Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial

M. Territo, H. Lazarus, R. Maziarz, 2003, Annals of Internal Medicine.

Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.

J. Dipersio, J. Kurtzberg, M. Boeckh, 2010, Blood.

Results of a Randomized, Double-Blind Trial of Fluconazole (FLU) vs. Voriconazole (VORI) for the Prevention of Invasive Fungal Infections (IFI) in 600 Allogeneic Blood and Marrow Transplant (BMT) Patients.

J. Dipersio, J. Kurtzberg, M. Boeckh, 2007 .

Emergence of Cunninghamella as a pathogenic invasive mold infection in allogeneic transplant recipients.

R. Maziarz, L. Strasfeld, J. Gajewski, 2013, Clinical lymphoma, myeloma & leukemia.

Management of Immune Compromised Transplant and Immune Effector Cell Treated Patients in the Setting of the COVID-19 Viral Pandemic: The OHSU Experience

R. Maziarz, B. Hayes-Lattin, 2021 .

A pilot study of the efficacy and safety of empiric daptomycin therapy in oncology patients with fever and severe neutropenia

R. Kullar, R. Maziarz, J. Bubalo, 2013, Therapeutic advances in infectious disease.

Post-Transplant cyclophosphamide is associated with increase in Non-CMV Herpesvirus infections in Acute leukemia and MDS patients.

M. Perales, H. Lazarus, K. Komanduri, 2021, Transplantation and cellular therapy.

M. Pasquini, K. Ballen, H. Lazarus, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation.

S. Heimfeld, D. Maloney, W. Leisenring, 1999, Blood.

Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation

S. Heimfeld, D. Maloney, W. Leisenring, 1999 .

CNS Remission Predicts Survival After Autologous Hematopoietic Stem Cell Transplantation (AHCT) For Non-Hodgkin Lymphoma (NHL) With Pre-Existing CNS Involvement: A CIBMTR Analysis

S. Montoto, P. Hari, H. Lazarus, 2010 .

Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.

J. Klein, M. Tallman, A. Keating, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades

P. Hari, M. Sorror, M. Maris, 2020, Haematologica.

Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.

E. Estey, M. Sorror, M. Maris, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune evasion by neocartilage-derived chondrocytes: Implications for biologic repair of joint articular cartilage.

C. Milliman, P. Streeter, R. Maziarz, 2010, Stem cell research.

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.

M. Maris, R. Storb, B. Sandmaier, 2004, Blood.

Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.

G. Salles, U. Jaeger, H. Holte, 2020, Blood advances.

Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.

J. Cortes, C. Abboud, G. Schiller, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

J. Vose, P. Hari, R. Gale, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation

M. Sorror, R. Storb, B. Sandmaier, 2008, Cancer.

Validation and Refinement Of The Disease Risk Index For Stratification Of Patients Undergoing Allogeneic Stem Cell Transplantation: A Study Of 13,131 Patients From The Center For International Blood & Marrow Transplant Research

M. Horowitz, R. Soiffer, M. Kalaycio, 2013 .

Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial.

D. Zahrieh, R. Soiffer, Stephanie J. Lee, 2004, Blood.

Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.

H. Deeg, B. Wood, M. Sorror, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.

P. Hari, M. Sorror, R. Storb, 2009, Blood.

Chromosome 1 Abnormalities Predict Shortened Progression Free and Overall Survival in Patients with High Risk Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation, a Retrospective Analysis

E. Medvedova, R. Maziarz, Yiyi Chen, 2014 .

Brefeldin A-mediated apoptosis requires the activation of caspases and is inhibited by Bcl-2.

H. Guo, R. Maziarz, H. Allen, 1998, Experimental cell research.

Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells.

Gordon Royle, M. Heinrich, M. Grompe, 1997, Blood.

Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.

M. Maris, R. Storb, B. Sandmaier, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.

R. Greil, M. Kersten, I. Flinn, 2021, The New England journal of medicine.

Graft‐versus‐host disease after liver transplantation is associated with bone marrow failure, hemophagocytosis, and DNMT3A mutations

A. Olyaei, S. Orloff, R. Maziarz, 2021 .

Induction of SIV capsid-specific CTL and mucosal sIgA in mice immunized with a recombinant S. typhimurium aroA mutant.

F. Heffron, R. Maziarz, M. Rivera, 1996, Vaccine.

Inactivation of the Fanconi anemia group C gene augments interferon-gamma-induced apoptotic responses in hematopoietic cells.

M. Grompe, R. Maziarz, R K Rathbun, 1997, Blood.

Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma

Scott E. Smith, Sin-Ho Jung, K. Owzar, 2017, The Lancet. Haematology.

Adult adherent stromal cells in the management of graft-versus-host disease

R. Maziarz, R. Deans, L. Newell, 2014, Expert opinion on biological therapy.

The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.

Jeffrey A. Cohen, A. Bartholomew, H. Lazarus, 2012, Immunotherapy.

Mesenchymal Stromal Cells: Impact on Hematopoietic Cell Transplantation

H. Lazarus, R. Maziarz, 2021, Blood and Marrow Transplant Handbook.

Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.

Andrea Bacigalupo, Philip McCarthy, E. Shpall, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T‐Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes

Y. Oki, Y. Nieto, D. Chihara, 2018, Clinical lymphoma, myeloma & leukemia.

HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.

R. Schlenk, H. Döhner, A. Ganser, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Surgical complications of bone marrow transplantation.

R. Maziarz, B. Sheppard, Andrew Jones, 2003, American journal of surgery.

Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study.

Alan M. Miller, P. D. Dal Cin, J. Sierra, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Non-MHC-restricted target-cell lysis by a CD4-CD8- TCR alpha beta T-cell line, as well as by TCR gamma delta T-cell lines, results from lymphokine-activated killing.

J. Strominger, R. Maziarz, S. Burakoff, 1991, International journal of cancer.

Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation.

J. Klein, D. Friedman, K. Ballen, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Incidence and impact of community respiratory viral infections in post‐transplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis and haploidentical stem cell transplantation

M. Perales, M. Krem, P. Ljungman, 2021, British journal of haematology.

REGULATION OF CYTOTOXIC T LYMPHOCYTE‐MEDIATED GRAFT REJECTION FOLLOWING BONE MARROW

B. Smith, B. Bierer, S. Emerson, 1988, Transplantation.

Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors

M. Maris, R. Storb, B. Sandmaier, 2006 .

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Relapsed or Refractory Follicular Lymphoma.

M. Maris, R. Storb, B. Sandmaier, 2005 .

Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS).

J. Cortes, M. Horowitz, M. Kalaycio, 2013, Blood.

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.

W. Wood, M. Sorror, F. Baron, 2017, Blood.

A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma.

Alan M. Miller, J. Armitage, J. Vose, 2003, Blood.

Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.

H. Deeg, M. Sorror, M. Maris, 2014, Blood.

Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors.

R. Maziarz, L. Newell, S. Slater, 2019, Cytotherapy.

Informal caregiving in Hematopoietic Blood and Marrow Transplant patients.

L. Nail, D. Eldredge, R. Maziarz, 2011, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.

J. Ritz, P. Westervelt, J. Dipersio, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma

Scott E. Smith, Sin-Ho Jung, K. Owzar, 2017, The Lancet. Haematology.

Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.

P. Hari, M. Sorror, M. Maris, 2011, JAMA.

Pre-Transplant C-Reactive Protein (CRP), Ferritin and Albumin As Biomarkers to Predict Transplant Related Mortality (TRM) after Allogeneic Hematopoietic Cell Transplant (HCT)

M. Pasquini, U. Popat, Xiaochun Zhu, 2014 .

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

Ruta Bajorunaite, Arturo Molina, John Gibson, 2003, Blood.

A Multicenter Retrospective Analysis of Outcomes and Toxicities with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

P. Riedell, M. Perales, D. Porter, 2020 .

Salvage second hematopoietic cell transplantation in myeloma.

J. Vose, A. Krishnan, S. Lonial, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens.

J. Cortes, M. Aljurf, I. Lewis, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CD25 expression distinguishes functionally distinct alloreactive CD4 CD134 (OX40) T-cell subsets in acute graft-versus-host disease.

A. Weinberg, P. Streeter, Xingqi Zhang, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome

E. Leifer, P. Westervelt, F. Appelbaum, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

E. Leifer, P. Westervelt, F. Appelbaum, 2020, Transplantation and Cellular Therapy.

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYCOSIS FUNGOIDES AND SEZARY SYNDROME

Alan M. Miller, J. Vose, S. Montoto, 2014, Bone Marrow Transplantation.

Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate

R. Braziel, B. Druker, M. Loriaux, 2003, Leukemia.

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia

D. Bottomly, S. McWeeney, B. Druker, 2022, Blood advances.

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.

J. Cortes, M. Aljurf, M. Tallman, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.

M. Sorror, R. Storb, B. Sandmaier, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic stem cell transplantation in fully MHC-matched Mauritian cynomolgus macaques recapitulates diverse human clinical outcomes

Tonya Swanson, A. Legasse, M. Axthelm, 2017, Nature Communications.

Multi‐centre validation of the prognostic value of the haematopoietic cell transplantation‐ specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation

M. Sorror, M. Maris, R. Storb, 2015, British journal of haematology.

Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

J. Radich, M. Sorror, R. Storb, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence and Impact of Cytomegalovirus Infection in Haploidentical and Matched-Related Donors Receiving Post-Transplant Cyclophosphamide (PTCy): A CIBMTR Analysis

M. Perales, K. Komanduri, R. Maziarz, 2020 .

Recombination hotspot associated factors specifically recognize novel target sequences at the site of interchromosomal rearrangements in T-ALL patients with t(8;14)(q24;q11) and t(1;14)(p32;q11).

J. Strominger, Y. Matsuo, J. Minowada, 1994, International immunology.

Nuclear proteins binding to a novel target sequence within the recombination hotspot regions of Bcl-2 and the immunoglobulin DH gene family.

J. Strominger, J. Minowada, R. Maziarz, 1994, Oncogene.

Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation.

J. Cortes, M. Aljurf, J. Szer, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.

J. Cortes, M. Aljurf, J. Szer, 2013, Blood.

Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

M. Sorror, R. Storb, B. Sandmaier, 2010 .

Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?

J. Cortes, M. Aljurf, I. Lewis, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Non‐myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B‐cell lymphoma: a multicentre experience

M. Sorror, R. Storb, B. Sandmaier, 2008, British journal of haematology.

with TBI following cyclophosphamide in combination with busulfan compared Better leukemia-free and overall survival in AML in first remission

J. Cortes, M. Aljurf, J. Szer, 2013 .

Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever

R. Maziarz, J. Bubalo, G. Cherala, 2009, Antimicrobial Agents and Chemotherapy.

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

M. Levis, M. Patnaik, A. Deol, 2020, Bone Marrow Transplantation.

Transplantation for CML: 2010.

R. Maziarz, 2010, Blood.

860 1 1 M a R C H 2 0 1 0 I V O L U M E 1 1 5 , N U M B E R 1 0 Blood

R. Maziarz, 2010 .

Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse rates.

R. Maziarz, L. Newell, R. Cook, 2023, Cytotherapy.

A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

P. Riedell, M. Perales, D. Porter, 2019, Blood.

An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL)

G. Salles, U. Jaeger, H. Holte, 2018 .

Viral opportunistic infections in Mauritian cynomolgus macaques undergoing allogeneic stem cell transplantation mirror human transplant infectious disease complications

Eisa Mahyari, Tonya Swanson, A. Legasse, 2020, Xenotransplantation.

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

M. Sorror, D. Maloney, C. Turtle, 2022, Blood.

Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial

G. Salles, U. Jaeger, Xia Han, 2020 .

Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy.

R. Vij, P. McCarthy, B. Logan, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bendamustine is Safe and Effective for Lymphodepletion Before Tisagenlecleucel in Patients with Refractory or Relapsed Large B-Cell Lymphomas.

U. Jäger, R. Maziarz, M. Ruella, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.

P. Curtin, T. Kovacsovics, E. Nemecek, 2015, Biology of Blood and Marrow Transplantation.

Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL

R. Maziarz, J. Gauthier, 2022, Nature reviews. Clinical oncology.

Thymectomized, irradiated, and bone marrow-reconstituted chimeras have normal cytolytic T lymphocyte precursors but a defect in lymphokine production.

R. Maziarz, S. Burakoff, V. Duprez, 1984, Journal of immunology.

Post-transplant Relapse

R. Maziarz, S. Slater, 2010 .

Long‐term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

P. Hari, M. Sorror, M. Maris, 2015, Cancer.

Long-Term Follow-up of Tisagenlecleucel in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study

M. Kersten, G. Salles, U. Jaeger, 2019, Biology of Blood and Marrow Transplantation.

Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel

M. Kersten, G. Salles, U. Jaeger, 2019, Blood.

TRANSPLANTATION Validation and re fi nement of the Disease Risk Index for allogeneic stem cell transplantation

M. Horowitz, P. Armand, R. Soiffer, 2014 .

Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.

J. Vose, Sonali M. Smith, P. Hari, 2008, Biology of Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplant for prolymphocytic leukemia.

J. Cortes, J. Szer, M. Horowitz, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) for Refractory Waldenstrom’s Macroglobulinemia (WM): Evidence for a Graft-Versus-WM Effect.

M. Maris, R. Storb, B. Sandmaier, 2006 .

M. Maris, B. Sandmaier, D. Maloney, 2004 .

Risk Factors and Impact of non-Aspergillus mold infections (NAMI) following Allogeneic HCT: A CIBMTR Infection & Immune Reconstitution analysis

J. Wingard, C. Bennett, S. Trifilio, 2015, Bone Marrow Transplantation.

J. Sierra, M. Tallman, R. Gale, 2008, Blood.

Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia.

H. Deeg, D. Porter, J. Cortes, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Expression of the major histocompatibility antigens HLA-A2 and HLA-B7 by DNA-mediated gene transfer.

P. A. Biro, M. van de Rijn, H. Spits, 1983, Journal of Immunology.

Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis

J. Wingard, C. Bennett, S. Trifilio, 2016, Bone Marrow Transplantation.

The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes

M. Pasquini, A. Wickrema, U. Popat, 2016, Haematologica.

Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia.

B. Sandmaier, R. Gale, H. Khoury, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Diffuse large B-cell lymphoma in adults aged 75 years and older: a single institution analysis of cause-specific survival and prognostic factors

R. Braziel, R. Maziarz, J. Dunlap, 2013, Therapeutic advances in hematology.

Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.

M. Aljurf, J. Szer, M. Tallman, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic Cell Transplants (HCT) from HLA-Matched Related (MRD) and Unrelated (URD) Donors for Patients with Hematologic Malignancies Using Low-Dose TBI Conditioning.

M. Maris, R. Storb, B. Sandmaier, 2005 .

Post-allogeneic stem cell transplant FLT3- targeted maintenance therapy: updates and considerations for clinical practice

R. Maziarz, Jonathan Cohen, 2022, Archives of stem cell and therapy.

Recipe for a graft: T cell dose remains elusive.

R. Maziarz, R. Cook, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Transplantation for CML: lifelong PCR monitoring?

R. Maziarz, 2006 .

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years.

M. Sorror, M. Maris, R. Storb, 2008 .

Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3-ITD-Mutated AML

M. Patnaik, A. Deol, R. Maziarz, 2018, Blood.

High dose chemotherapy—results of American studies

R. Maziarz, Craig R. Nichols, 1999, International journal of cancer.

lymphoblastic leukemia in first complete remission Unrelated donor transplants in adults with Philadelphia-negative acute

J. Sierra, R. Gale, M. Bishop, 2011 .

Radius: Midostaurin (mido) Plus Standard of Care (SOC) after Allogeneic Stem Cell Transplant (alloSCT) in Patients (pts) with FLT3-Internal Tandem Duplication (ITD)–Mutated Acute Myeloid Leukemia (AML)

M. Levis, M. Patnaik, A. Deol, 2019, Biology of Blood and Marrow Transplantation.

Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.

J. Sierra, A. Zander, M. Horowitz, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

M. Maris, R. Storb, B. Sandmaier, 2004 .

Outcomes of hematologic malignancies after unrelated donor hematopoietic cell transplantation according to place of residence.

J. Klein, Stephanie J. Lee, H. Lazarus, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic cell transplantation in 2020: summary of year 2 recommendations of the National Marrow Donor Program's System Capacity Initiative.

A. Bracey, C. Anasetti, R. Champlin, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Treatment with AMD3100 in Multiple Myeloma or Non-Hodgkin’s Lymphoma Patients to Increase the Number of Peripheral Blood Stem Cells When Given with a Mobilizing Regimen of Chemotherapy and G-CSF.

A. Nademanee, J. Liesveld, L. Akard, 2004 .

K. Ballen, H. Lazarus, L. Isola, 2008 .

Autologous bone marrow transplantation in primary breast cancer : the American experience

J. Fay, L. Akard, C. Cirrincione, 1995 .

The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy

M. Bonafede, R. Maziarz, J. Tkacz, 2020, Leukemia & lymphoma.

Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma

Philipp W. Raess, R. Braziel, K. Chansky, 2018, Leukemia & lymphoma.

CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL‐TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS

M. Kersten, G. Salles, U. Jaeger, 2019, Hematological Oncology.

A phase 1 study of lucatumumab, a fully human anti‐CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma

S. Jagannath, B. Ewald, R. Maziarz, 2012, British journal of haematology.

Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis.

R. Maziarz, B. Tomkinson, J. Sullivan, 1989, Journal of immunology.

A randomized, double-blinded, pilot trial of aprepitant added to standard antiemetics during conditioning therapy for hematopoietic stem cell transplant (HSCT)

P. Curtin, R. Maziarz, J. McCune, 2007 .

Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation.

R. Maziarz, J. Bubalo, S. Karbowicz, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Pre‐transplant comorbidity burden and post‐transplant chronic graft‐versus‐host disease

M. Sorror, R. Storb, B. Sandmaier, 2015, British journal of haematology.

A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. Placebo+G-CSF in Non-Hodgkin’s Lymphoma (NHL) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

J. Dipersio, G. Bridger, G. Calandra, 2007 .

Successful Stem Cell Mobilization Rescue by AMD3100 (Plerixafor)+G-CSF for Patients Who Failed Primary Mobilization: Results from the Phase III (3101-NHL) Study.

J. Dipersio, G. Bridger, G. Calandra, 2007 .

Terumo spectra optia leukapheresis of cynomolgus macaques for hematopoietic stem cell and T cell collection

Tonya Swanson, A. Legasse, M. Axthelm, 2020, Journal of clinical apheresis.

Allogeneic stem cell transplantation in fully MHC-matched Mauritian cynomolgus macaques recapitulates diverse human clinical outcomes

Charles R. Thomas, Tonya Swanson, A. Legasse, 2017, Nature Communications.

The Translin Ring Specifically Recognizes DNA Ends at Recombination Hot Spots in the Human Genome*

J. Strominger, A. Omori, R. Maziarz, 1997, The Journal of Biological Chemistry.

Dissection of the Human Multipotent Adult Progenitor Cell Secretome by Proteomic Analysis

P. Wilmarth, R. Maziarz, A. Reddy, 2013, Stem cells translational medicine.

Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma

P. Riedell, M. Perales, D. Porter, 2023, Transplantation and cellular therapy.

Allogeneic immunity clears latent virus following allogeneic stem cell transplantation in SIV-infected ART-suppressed macaques.

R. Siliciano, J. Siliciano, Tonya Swanson, 2023, Immunity.

Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)—An Interim Analysis

G. Salles, H. Holte, U. Jäger, 2017 .

GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19‐TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS

G. Salles, H. Holte, U. Jäger, 2017 .

The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: a health care resource and infrastructure assessment.

D. Weisdorf, A. Bracey, C. Anasetti, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Yan Song, A. Sung, W. Hwang, 2022, Transplantation and cellular therapy.

Impact of Pre-Transplant Comorbidities on the Rate of- and Mortality-Following Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation (HCT)

M. Sorror, R. Storb, B. Sandmaier, 2011 .

Standardization of terminology for episodes of hematopoietic stem cell patient transplant care.

S. Crawford, R. Maziarz, J. Gajewski, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Radius: A Phase 2, Randomized Trial of Standard of Care (SOC) with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT) in Patients (pts) with FLT3-Itd-Mutated Acute Myeloid Leukemia (AML)

M. Patnaik, A. Deol, R. Maziarz, 2016 .

Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome : Results of a Randomized Comparative Phase III Study.

J. Cortes, C. Abboud, G. Schiller, 2008 .

Anakinra for refractory CRS or ICANS after CAR T-cell therapy.

D. Maloney, C. Turtle, E. Nemecek, 2023, Transplantation and cellular therapy.

Consensus Grading of Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel on the JULIET Study

D. Maloney, S. Schuster, F. Locke, 2018, Blood.

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

P. Riedell, M. Perales, D. Porter, 2022, Blood advances.

Hematopoietic stem cell transplantation and implications for cell therapy reimbursement.

R. Maziarz, Dawn Driscoll, 2011, Cell stem cell.

Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.

J. Kurtzberg, O. Frankfurt, D. Cilloni, 2023, Transplantation and cellular therapy.

Multi-Institutional Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes

M. Sorror, R. Storb, B. Sandmaier, 2011 .

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

P. Riedell, F. Awan, M. Bishop, 2022, Blood.

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

R. Greil, M. Kersten, Y. Kwong, 2021, New England Journal of Medicine.

High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia

H. Erickson, J. Tyner, M. Loriaux, 2009, Leukemia.

A randomized, placebo-controlled pilot trial of aprepitant combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic stem cell transplant (HSCT)

R. Maziarz, J. Bubalo, G. Meyers, 2018, Bone Marrow Transplantation.

A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

J. Ritz, P. Westervelt, J. Dipersio, 2016 .

Clinical and Economic Burden of Multiple dsDNA Viral Infections After Allogeneic Hematopoietic Cell Transplantation.

M. Boeckh, R. Maziarz, A. Chandak, 2022, Transplantation and cellular therapy.

Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes

J. Jorgensen, R. Champlin, R. Maziarz, 2017, Bone Marrow Transplantation.

Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning after Failed Myeloablative HCT: Factors Affecting Outcomes.

M. Sorror, R. Storb, F. Baron, 2005 .

Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease.

R. Storb, F. Appelbaum, T. Gooley, 1996, Bone marrow transplantation.

Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen

D. Maloney, F. Appelbaum, R. Maziarz, 2003, Bone Marrow Transplantation.

Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

B. Barlogie, S. Jagannath, S. Lonial, 2006 .

Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single dose velafermin (CG53135-05) for the prevention of oral mucositis.

E. Anaissie, Y. Halvorsen, R. Maziarz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Isolation in the allogeneic transplant environment: how protective is it?

R. Maziarz, B. Hayes-Lattin, J. Leis, 2005, Bone Marrow Transplantation.

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia

M. Maris, R. Storb, B. Sandmaier, 2008 .

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.

J. Cortes, M. Aljurf, J. Szer, 2013, Blood.

Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

J. Vose, Sonali M. Smith, P. Hari, 2012, Blood.

Peripheral-blood stem cells versus bone marrow from unrelated donors.

P. Westervelt, S. Mineishi, D. Porter, 2012, The New England journal of medicine.

High-dose busulfan, melphalan and thiotepa as consolidation for non-inflammatory high-risk breast cancer

R. Livingston, F. Appelbaum, R. Maziarz, 2000, Bone Marrow Transplantation.

Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?

R. Maziarz, 2008, Current opinion in hematology.

Impact of Prior Therapy with Imatinib Mesylate on the Outcome of Hematopoietic Cell Transplantation (HCT) for Chronic Myeloiod Leukemia (CML).

J. Szer, Stephanie J. Lee, Tao Wang, 2007 .

Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

M. Sorror, M. Maris, R. Storb, 2008 .

Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization

A. Nademanee, J. Liesveld, G. Bridger, 2010, Bone Marrow Transplantation.

Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient.

M. Perales, S. Devine, R. Maziarz, 2023, Transplantation and cellular therapy.

Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium

P. Riedell, M. Gonen, M. Perales, 2022, Blood.

Bendamustine Is a Safe and Effective Regimen for Lymphodepletion before Tisagenlecleucel in Patients with Large B-Cell Lymphomas

U. Jaeger, D. Porter, S. Schuster, 2021, Blood.

Diffuse large B-cell lymphoma in adults aged 75 years and older: a single institution analysis of cause-specific survival and prognostic factors

R. Braziel, R. Maziarz, J. Dunlap, 2013, Therapeutic advances in hematology.

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.

A. Zander, J. Szer, M. Horowitz, 2008, Blood.

Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma

R. Maziarz, B. Hayes-Lattin, T. Bains, 2014, Leukemia & lymphoma.

Long-term Outcomes After Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma - The Oregon Health and Science University Experience.

R. Maziarz, L. Schachter, B. Hayes-Lattin, 2023, Clinical lymphoma, myeloma & leukemia.

Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102

L. Steuten, P. Westervelt, J. Pidala, 2024, JCO oncology practice.

Managing particulates in cellular therapy.

M. Mccaman, R. Maziarz, J. Rowley, 2012, Cytotherapy.

Abandonment of high-dose chemotherapy/hematopoietic cell transplants for breast cancer following negative trial results.

P. McCarthy, H. Lazarus, D. Howard, 2011, Health services research.

Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.

R. Vij, W. Wood, J. Cortes, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?

M. Perales, A. Alousi, R. Champlin, 2013, Blood.

Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy

D. Maloney, C. Turtle, R. Maziarz, 2021, Blood.

Enhanced Survival of Chronic Myelomonocytic Leukemia (CMML)-Dysplastic over Proliferative Subtype After Allogeneic Hematopoietic Cell Transplant: A Tertiary Center Experience and Literature Review.

R. Maziarz, Jennifer N. Saultz, Y. Migdady, 2024, Acta haematologica.

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

P. Riedell, M. Gonen, M. Perales, 2023, Blood advances.

Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial.

P. Hari, R. Storb, B. Sandmaier, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study.

P. Westervelt, A. Alousi, R. Maziarz, 2023, Bone marrow transplantation.

Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation.

M. Norkin, M. Perales, S. Mineishi, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.